Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Beam Therapeutics (BEAM) Shares Outstanding (2019 - 2025)

Historic Shares Outstanding for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to $101.4 million.

  • Beam Therapeutics' Shares Outstanding rose 2277.27% to $101.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $101.4 million, marking a year-over-year increase of 2277.27%. This contributed to the annual value of $83.6 million for FY2024, which is 245.07% up from last year.
  • According to the latest figures from Q3 2025, Beam Therapeutics' Shares Outstanding is $101.4 million, which was up 2277.27% from $100.8 million recorded in Q2 2025.
  • In the past 5 years, Beam Therapeutics' Shares Outstanding registered a high of $101.4 million during Q3 2025, and its lowest value of $61.7 million during Q1 2021.
  • Its 5-year average for Shares Outstanding is $78.5 million, with a median of $78.0 million in 2023.
  • Per our database at Business Quant, Beam Therapeutics' Shares Outstanding surged by 3429.06% in 2021 and then skyrocketed by 245.07% in 2024.
  • Quarter analysis of 5 years shows Beam Therapeutics' Shares Outstanding stood at $68.4 million in 2021, then increased by 4.22% to $71.3 million in 2022, then rose by 14.53% to $81.6 million in 2023, then increased by 2.45% to $83.6 million in 2024, then grew by 21.2% to $101.4 million in 2025.
  • Its Shares Outstanding stands at $101.4 million for Q3 2025, versus $100.8 million for Q2 2025 and $100.6 million for Q1 2025.